• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors".

作者信息

Michiels Stefan, Saad Everardo D, Buyse Marc

机构信息

Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Villejuif, 94805, France.

Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM U1018, Villejuif, 94805, France.

出版信息

Drugs. 2017 Jul;77(10):1139-1140. doi: 10.1007/s40265-017-0761-x.

DOI:10.1007/s40265-017-0761-x
PMID:28573433
Abstract
摘要

相似文献

1
Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors".
Drugs. 2017 Jul;77(10):1139-1140. doi: 10.1007/s40265-017-0761-x.
2
Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
Drugs. 2017 Jul;77(10):1137-1138. doi: 10.1007/s40265-017-0760-y.
3
Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.无进展生存期可作为晚期实体瘤靶向治疗临床试验中总生存期的替代指标。
Drugs. 2017 May;77(7):713-719. doi: 10.1007/s40265-017-0728-y.
4
Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.无进展生存期作为实体瘤的一个终点——来自临床试验和临床实践的观点
Eur J Cancer. 2014 Sep;50(13):2303-8. doi: 10.1016/j.ejca.2014.05.024. Epub 2014 Jun 25.
5
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms.无进展生存期作为晚期神经内分泌肿瘤的替代终点
Endocr Relat Cancer. 2017 Sep;24(9):475-483. doi: 10.1530/ERC-17-0197. Epub 2017 Jul 6.
6
Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.当代晚期卵巢癌 III 期临床试验终点：评估客观缓解率、无进展生存期和总生存期的优缺点。
Gynecol Oncol. 2015 Jan;136(1):121-9. doi: 10.1016/j.ygyno.2014.10.010. Epub 2014 Oct 24.
7
Surrogate endpoints in breast cancer screening trials - Authors' reply.
Lancet Oncol. 2022 Aug;23(8):e361. doi: 10.1016/S1470-2045(22)00396-5.
8
Progression-free survival ratio as end point for phase II trials in advanced solid tumors.无进展生存率作为晚期实体瘤II期试验的终点指标。
J Clin Oncol. 2011 May 20;29(15):e451-2; author reply e453. doi: 10.1200/JCO.2010.34.0380. Epub 2011 Apr 4.
9
Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.一线化疗治疗晚期胰腺癌中无进展生存期作为总生存期的替代指标。
Eur J Cancer. 2016 Sep;65:11-20. doi: 10.1016/j.ejca.2016.05.016. Epub 2016 Jul 21.
10
Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.评估无进展生存期作为化疗和靶向药物转移性结直肠癌试验中生存的替代终点。
Clin Cancer Res. 2013 Mar 1;19(5):969-76. doi: 10.1158/1078-0432.CCR-12-2502. Epub 2013 Jan 9.

引用本文的文献

1
Physicians' Perception of the Evidence in Relation to Primary Endpoints of Clinical Trials on Breast Cancer.医生对与乳腺癌临床试验主要终点相关证据的认知。
Breast Care (Basel). 2022 Apr;17(2):180-187. doi: 10.1159/000518260. Epub 2021 Aug 20.

本文引用的文献

1
Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
Drugs. 2017 Jul;77(10):1137-1138. doi: 10.1007/s40265-017-0760-y.
2
Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.无进展生存期可作为晚期实体瘤靶向治疗临床试验中总生存期的替代指标。
Drugs. 2017 May;77(7):713-719. doi: 10.1007/s40265-017-0728-y.
3
Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events.
J Biopharm Stat. 2017;27(6):1043-1053. doi: 10.1080/10543406.2017.1295249. Epub 2017 Mar 20.
4
Assessing survival benefit when treatment delays disease progression.评估治疗延缓疾病进展时的生存获益。
Clin Trials. 2016 Jun;13(3):352-7. doi: 10.1177/1740774515625990. Epub 2016 Feb 22.
5
Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials.为何进展后生存期和复发后生存期并非癌症随机临床试验中疗效的恰当衡量指标。
Int J Cancer. 2015 May 15;136(10):2444-7. doi: 10.1002/ijc.29278. Epub 2014 Nov 3.